SCHEMBL5460460

SCHEMBL5460460

CCOc1cccc(NC(=O)Nc2ccc(N3CCNCC3)cc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.60
MEN1 O00255 5/20 0.60
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
MAPT P10636 9/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
ALDH1A1 P00352 3/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
MITF O75030 1/20 0.52
PAX8 Q06710 1/20 0.52
MAPK1 P28482 2/20 0.52
HSD17B10 Q99714 2/20 0.50
ALOX15 P16050 1/20 0.50
P2RY1 P47900 1/20 0.49
EPHX2 P34913 3/20 0.48
KDM4E B2RXH2 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5462780 0.88 MAPT (0.62) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL5467016 0.87 TP53 (0.64) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL5466996 0.86 DGAT1 (0.55) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL5460071 0.86 KMT2A (0.59) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL5455863 0.82 KMT2A (0.62) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL5456796 0.81 NAMPT (0.56) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL4111978 0.80 NPC1 (0.75) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL5462738 0.80 JAK3 (0.55) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL5465106 0.79 MAPT (0.61) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL4112735 0.79 NPC1 (0.68) KMT2AMEN1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 KMT2A 1350/4885MEN1 1828/4885NPC1 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.